MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Stock Position in Illumina, Inc. (NASDAQ:ILMN)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 66.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 52,438 shares of the life sciences company's stock after selling 101,971 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Illumina were worth $7,006,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ILMN. Capital World Investors boosted its position in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after acquiring an additional 14,481,232 shares during the last quarter. WCM Investment Management LLC raised its stake in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after purchasing an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Brown Advisory Inc. lifted its position in Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after purchasing an additional 1,909,118 shares during the last quarter. Finally, Norges Bank purchased a new position in Illumina in the 4th quarter worth approximately $228,714,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In related news, CFO Ankur Dhingra acquired 6,100 shares of the firm's stock in a transaction on Monday, May 12th. The stock was acquired at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 2.60% of the stock is owned by company insiders.

Illumina Trading Down 1.1%

NASDAQ:ILMN traded down $0.91 during midday trading on Friday, reaching $79.63. 380,673 shares of the stock traded hands, compared to its average volume of 2,314,537. The stock has a market capitalization of $12.60 billion, a P/E ratio of -10.37, a PEG ratio of 1.60 and a beta of 1.35. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a fifty day moving average of $78.23 and a 200 day moving average of $109.53. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.98 earnings per share. On average, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ILMN shares. Guggenheim lowered their price objective on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. TD Cowen cut Illumina from a "buy" rating to a "hold" rating and cut their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $128.15.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.